Skip to main content
. 2023 Jan 12;15:1006125. doi: 10.3389/fnmol.2022.1006125

Figure 6.

Figure 6

Inhibiting ASIC1a in the CeA reverses inflammatory pain hypersensitivity and anxiety-like behaviors. (A) Schematic diagram of the pharmacological experimental procedure. (B) Mechanical pain thresholds of CFA 1D mice following the CeA injection of PcTx1 for 2 h (CFA-ACSF, n = 7 mice; CFA-PcTx1, n = 7 mice; F(1,12) = 50.97, p < 0.0001). (C) Mechanical pain thresholds of CFA 1D mice following the CeA injection of PcTx1 for 1 week (CFA-ACSF, n = 7 mice; CFA-PcTx1, n = 7 mice; F(1,12) = 42.03, p < 0.0001). (D) A pharmacological experimental procedure. (E,H) Heatmaps showing the locomotion traces of CFA-ACSF mice and CFA-PcTx1 mice in the open field test (OFT) and elevated plus maze test (EPMT). (F,G,I) Behavioral effects of the pharmacological inhibition of ASIC1a in the CeA in OPT and EPMT (F, CFA-ACSF, n = 8 mice,CFA-PcTx1, n = 9 mice in OFT; entries into center in OFT, t15 = 2.655, p = 0.018; time in center in OFT, t15 = 2.436, p = 0.0278; G, total distances in OFT, t15 = 0.9944, p = 0.3358; I, CFA-ACSF, n = 11 mice, CFA-PcTx1, n = 16 mice in EPMT; entries into the open arms in EPMT, t25 = 2.174, p = 0.0394; time in the open arms in EPMT, t25 = 2.626, p = 0.0145). (J,K) Sample traces (J) and statistical data (K) for action potential firing recorded from GABACeA in CFA 1D mice treated with ACSF or PcTx1 (n = 17 cells from four mice per group; F(1,32) = 10.66, p = 0.0026). (L) Summary of the rheobases of action potentials from CFA 1D mice treated with ACSF or PcTx1 (n = 17 cells from four mice per group; t32 = 0.7657, p = 0.4495). (M) The resting membrane potential (Vrest) showing no difference between CFA-ACSF mice and CFA-PcTx1 mice (n = 17 cells from four mice per group; t32 = 0.5323, p = 0.5982). All data are shown as the mean ± SEM, n.s., not significant; * p < 0.05; ** p < 0.01 and *** p < 0.001. Two-way repeated-measures ANOVA with Bonferroni post-hoc analysis for (B,C,K); unpaired t-test for (F,G,I,L,M).